U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H29N3O3
Molecular Weight 431.5277
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIRBANIBULIN

SMILES

c1ccc(cc1)CN=C(Cc2ccc(cn2)-c3ccc(cc3)OCCN4CCOCC4)O

InChI

InChIKey=HUNGUWOZPQBXGX-UHFFFAOYSA-N
InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)

HIDE SMILES / InChI

Molecular Formula C26H29N3O3
Molecular Weight 431.5277
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

KX-01 is a dual inhibitor of Src kinase and tubulin polymerization. KX01 promotes the induction of p53, G2/M arrest of proliferating cell populations and subsequent apoptosis via the stimulation of Caspase-3 and PARP cleavage. The drug was developed by Kinex Pharmaceuticals and reached phase II of clinical trials for the treatment of Castration-Resistant Prostate Cancer and Actinic Keratosis. KX-01 demonstrated good in vitro pofile against different cancer cell lines with IC50 in nanomolar range.

Approval Year

PubMed

PubMed

TitleDatePubMed
Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.
2009 Jul
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
2011 Apr 15
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
2012 Apr
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
2013 Aug
Patents

Sample Use Guides

Patients recieve 40 mg of oral KX-01 twice-daily. Ointment form should be applied once daily.
Route of Administration: Other
PC3-LN4 human prostate cancer cells were treated with 10(-4)-10(4) nM of KX-01 for 72 hours and GI50 value was determined to be 40 nM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:29:40 UTC 2021
Edited
by admin
on Fri Jun 25 21:29:40 UTC 2021
Record UNII
4V9848RS5G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIRBANIBULIN
USAN   INN  
Official Name English
KX2391
Code English
KX-2-391
Code English
KLISYRI
Brand Name English
2-PYRIDINEACETAMIDE, 5-(4-(2-(4-MORPHOLINYL)ETHOXY)PHENYL)-N-(PHENYLMETHYL)-
Systematic Name English
N-BENZYL-2-(5-(4-(2-MORPHOLIN-4-YLETHOXY)PHENYL)PYRIDIN-2-YL)ACETAMIDE
Systematic Name English
KX01
Code English
TIRBANIBULIN [INN]
Common Name English
TIRBANIBULIN [WHO-DD]
Common Name English
KX-01
Code English
TIRBANIBULIN [USAN]
Common Name English
KX-2391
Code English
KX2-391
Code English
Code System Code Type Description
FDA UNII
4V9848RS5G
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
ChEMBL
CHEMBL571546
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
DRUG BANK
DB06137
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
EPA CompTox
897016-82-9
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
NCI_THESAURUS
C74077
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
PUBCHEM
23635314
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
CAS
897016-82-9
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
INN
10864
Created by admin on Fri Jun 25 21:29:40 UTC 2021 , Edited by admin on Fri Jun 25 21:29:40 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MATE1
IC50
TRANSPORTER -> INHIBITOR
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by OATP1B3
IC50
BINDER->LIGAND
Plasma protein binding of tirbanibulin is 88% and is independent of concentrations in the range of 0.01 to 10 ?g/mL.
BINDING
METABOLIC ENZYME -> SUBSTRATE
MINOR
TARGET->INHIBITOR OF AGGREGATION
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by OCT1
IC50
TRANSPORTER -> INHIBITOR
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by OCT2
IC50
TRANSPORTER -> INHIBITOR
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MATE2-K
IC50
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> INHIBITOR
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by OATP1B1
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC